We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J’s Exit from DES Market Is Good News for Competitors
J&J’s Exit from DES Market Is Good News for Competitors
June 17, 2011
Johnson & Johnson (J&J)’s decision to discontinue working in the drug-eluting stent market is expected to benefit competitors such as Abbot Laboratories and Boston Scientific.